Advanced Cell Technology (ACTC.OB) awarded Single Blastomere Technique Patent
February 23rd, 2011
No comments
ACTC.OB has been issued patent #7,893,315 (2/23/11) Read more…
Archive
Archive for the ‘NASDAQ: ACTC.OB’ Category
Generating Platelets using iPSCs
January 13th, 2011
No comments
Pluripotent stem cells might one day provide a way to generate “an unlimited supply of platelets for transfusion” in the laboratory. Read more…
FDA Clearance for hESC Clinical Trial to Treat AMD, Advanced Cell Technology (ACTC.OB)
January 3rd, 2011
No comments
The US FDA has cleared the Investigational New Drug (IND) application Read more…
Categories: IND Application Cleared, NASDAQ: ACTC.OB, Stem Cell Technology
$25M Funding Commitment, Advanced Cell Technology (ACTC.OB)
December 31st, 2010
No comments
ACT or ACTC.OB has entered into a $25M non-convertible stock purchase agreement Read more…
Categories: Financing, NASDAQ: ACTC.OB, Stem Cell Technology
Blastomere Technology Agreement with Roslin Institute, Advanced Cell Technology (ACTC.OB)
December 28th, 2010
No comments
ACTC.OB has entered into a Memorandum of Understanding with Roslin Cells LTD (“Roslin Cells”) of Scotland, Read more…
Orphan Drug Designation filed in EU of Stargardt’s Disease, Advanced Cell Technology (ACTC.OB)
December 23rd, 2010
No comments
ACTC.OB has filed for Orphan Drug Designation with the European Medicines Agency (EMA) for its Retinal Pigment Epithelial (RPE) Cells Read more…
Categories: NASDAQ: ACTC.OB, Stem Cell Technology
Chairman and CEO William M. Caldwell IV dies, Advanced Cell Technology (ACTC.OB)
December 14th, 2010
No comments
It is with profound sorrow the passing of Chairman and Chief Executive Officer, William M. Caldwell IV. Read more…
Strengthening the Balance Sheet, Advanced Cell Technology(OTCBB: ACTC)
December 2nd, 2010
No comments
$3M in debt converted to equity, elimination of approximately $33M in indebtedness over past 14 months and convertible debentures reduced to $890K. Read more…
IND filed for first Clinical Trial using hESCs to treat Dry AMD, Advanced Cell Technology (ACTC.OB)
November 30th, 2010
No comments
ACTC.OB has filed an Investigational New Drug (IND) Application with the US FDA to initiate a Phase I/II multicenter study Read more…
Q3/10 Results, Advanced Cell Technology (ACTC.OB)
November 9th, 2010
No comments
ACTC.OB had a net loss of $1.9M or ($0.00) per share. Read more…
Categories: NASDAQ: ACTC.OB, OTC:BB:ACTC, Q3/10 Results, Stem Cell Technology
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.